Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Ultragenyx Pharmaceutical (NASDAQ:RARE) reaffirmed revenue and 2026 combined R&D and SG&A guidance, expecting flat to down low single digits from 2025, and at least a 15% decline in 2027. In Q2, Crysvita patient starts rose in Latin America and Turkey, and DOJOLVI had about 675 reimbursed patients in North America. FDA PDUFA dates are Aug. 23 for DTX-401 and Sept. 19 for UX-111.
How this was made
The 30-second read
Why it matters
Traders can frame the next decision-driven catalysts around FDA PDUFA dates for DTX-401 and UX-111, while using reaffirmed 2026 spending guidance to anchor expectations for operating cost trajectory.
Market read
Guidance reaffirmation plus two near-term FDA decision dates and an upcoming Phase III readout create a clear event calendar for positioning and hedging.
What to watch
The article notes UX143 (setrusumab) Phase III primary endpoint misses and UK may require a new randomized study, which could weigh on longer-dated pipeline sentiment despite near-term gene-therapy catalysts.
Background
This is a Q2 earnings call highlights recap covering guidance, commercial uptake for existing therapies, and upcoming regulatory decision and trial-readout timelines.
Ticker impact
Ultragenyx reaffirmed 2026 revenue and R&D/SG&A guidance and reiterated FDA PDUFA dates for DTX-401 (Aug. 23) and UX-111 (Sept. 19).
Moderate two-sided volatility into Aug. 23 and Sept. 19, with guidance reaffirmation limiting downside if outcomes are mixed.
The article provides specific regulatory timelines and reiterates spending guidance, but it does not disclose new trial efficacy results or an FDA decision outcome.
Market effects
Reinforces investor focus on rare-disease gene therapy timelines and payer readiness ahead of FDA decision dates.
Highlights expanding commercial reach in Latin America, Turkey, Europe, and Japan, which can support sentiment for global rare-disease commercialization.
Cross-border regulatory and reimbursement progress (Japan NHI listing, UK regulator stance) underscores global execution risk for gene-therapy launches.
Counterpoint
Even with reaffirmed guidance, the stock may trade more on binary FDA outcomes than on cost discipline or commercial patient counts.
Key entities
- companyUltragenyx Pharmaceutical
NASDAQ-listed rare-disease biopharma whose Q2 call reiterates guidance and provides FDA decision timelines for two investigational gene therapies.
- drug_programDTX-401
Investigational gene therapy for glycogen storage disease type Ia, with a PDUFA date of Aug. 23.
- drug_programUX-111
Investigational gene therapy for Sanfilippo syndrome type A, with a PDUFA date of Sept. 19.
- drug_programGTX-102 (apazunersen)
Phase III ASPIRE readout expected in September or October for Angelman syndrome.
- drug_programUX143 (setrusumab)
Phase III ORBIT and COSMIC studies did not meet primary endpoints; UK regulator may require a new randomized study.